• Citer

Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status

par Nuciforo, Paolo Giovanni;Aura, Claudia Monica;Holmes, Eileen;Prudkin, Ludmila;Molina Jimenez, José ;Martinez Aznar, Pablo ;de la Peña, Lorena;Ellis, Catherine;Eidtmann, Holger;Piccart-Gebhart, Martine ;Scaltriti., Maurizio;Baselga, José
Référence Annals of oncology, 26, 7, page (1494-1500)
Publication Publié, 2015-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Auteur:	Nuciforo, Paolo Giovanni; Aura, Claudia Monica; Holmes, Eileen; Prudkin, Ludmila; Molina Jimenez, José; Martinez Aznar, Pablo; de la Peña, Lorena; Ellis, Catherine; Eidtmann, Holger; Piccart-Gebhart, Martine; Scaltriti., Maurizio; Baselga, José
Informations sur la publication:	Annals of oncology, 26, 7, page (1494-1500)
Statut de publication:	Publié, 2015-07
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	Breast cancer
	HER2-positive
	Lapatinib
	PIK3CA
	PTEN
	Trastuzumab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdv175
	info:scp/84940187385